HOE140 Icatibant

Phase 2

Sanofi (SNY)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Joint Disease

View Full Landscape

Drug Information

Target Indication

Joint Disease

Clinical Trial

NCT00303056

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA7/16/2021

Icatibant Accord

Icatibant Accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1 esterase inhibitor deficiency.

View on EMA

EMA7/11/2008

Firazyr

Firazyr is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SNY

Sanofi

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

zolpidem-MR (SL800750)Phase 3

Sleep Initiation and Maintenance Disorders

efanesoctocog alfa (BIVV001)Phase 3

Hemophilia A

DuvakitugPhase 3

Ulcerative Colitis

xaliproden (SR57746A)Phase 3

Alzheimer Disease

A/H1N1 pandemic influenza vaccine (non- adjuvanted)Phase 3

Influenza

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts